New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

Q2 2025 Earnings Call Transcript July 29, 2025 Alkermes plc beats earnings expectations. Reported EPS is $0.517, expectations ...

In the highly competitive biotech industry, only a few standout companies attract Wall Street’s attention. Among them, two ...

Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.

A recent study published in Current Pharmaceutical Analysis explores the activity of the TNF-α system in patients with various brain disorders and during psychopharmacological treatment. The research ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at ...

This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...

Some non-ADHD students misuse stimulants like Ritalin, risking addiction. But children with ADHD who take psychostimulants ...

It began subtly. Anil Kumar, a 42-year-old chartered accountant from Kochi, found himself waking up at 2am most nights, ...

Second Quarter Revenues of $390.7 Million - - GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 - - Company Reiterates 2025 Financial Expectations ...

With the world on fire and the economy in crisis, many of us are struggling to get the recommended six to nine hours of sleep ...

- Diluted earnings per share (GAAP) reached $0.52 for Q2 2025, ahead of expectations by $0.16, and beating the $0.36 GAAP consensus estimate. - Revenue was $390.7 million, exceeding the $341.4 million ...